Miles - that drug progression chart is very interesting. #4mm for that one, plus some other DD info in one of your other posts.
This 10Q info lists some of the same info status on it, but it supports what you posted. Thank you. (buc invited me here to stop by and check out catalysts)
Form 10-Q for NEURALSTEM, INC.
12-Nov-2013
Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
We urge you to read this entire Quarterly Report on Form 10-Q, including the" Risk Factors" section, the financial statements, and related notes. As used in this Quarterly Report, unless the context otherwise requires, the words "we," "us," "our," "the Company," "Neuralstem" and "Registrant" refers to Neuralstem, Inc. Also, any reference to "common shares," or "common stock," refers to our $.01 par value common stock. The information contained herein is current as of the date of this Quarterly Report (September 30, 2013), unless another date is specified. We prepare our interim financial statements in accordance with U.S. GAAP. Our financial statements and results of operations as of and for the three- and nine-month periods ended September 30, 2013 are not necessarily indicative of our prospective financial condition and results of operations for the pending full fiscal year ending December 31, 2013. The interim financial statements presented in this Quarterly Report as well as other information relating to our company contained in this Quarterly Report should be read in conjunction and together with the reports, statements and information filed by us with the United States Securities and Exchange Commission or SEC.
Our Management's Discussion and Analysis of Financial Condition and Results of Operations or MD&A, is provided in addition to the accompanying financial statements and notes to assist readers in understanding our results of operations, financial condition and cash flows. Our MD&A is organized as follows:
? Executive Overview - Discussion of our business and overall analysis of financial and other highlights affecting the Company in order to provide context for the remainder of MD&A.
? Trends & Outlook - Discussion of what we view as the overall trends affecting our business and the strategy for 2013.
? Critical Accounting Policies- Accounting policies that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.
? Results of Operations- Analysis of our financial results comparing the three- and nine-month periods ended September 30, 2013 to the comparable period of 2012.
Page 14
? Liquidity and Capital Resources- An analysis of cash flows and discussion of our financial condition and future liquidity needs.
Executive Overview We are focused on the development and commercialization of treatments based on
(i) human neuronal stem cells and (ii) small molecule compounds. We are headquartered in Rockville, Maryland and have a wholly-owned subsidiary in China.
We have developed and maintain a portfolio of patents and patent applications that form the proprietary base for our research and development efforts in the area of neural stem cell research. We own or exclusively license forty-nine (49) U.S. or foreign issued patents and fifty-nine (59) U.S. and foreign patent applications in the field of regenerative medicine, related to our stem cell technologies as well as our small molecule compounds. At times, including in the third quarter of 2012 and first quarter of 2013, we have licensed the use of our intellectual property to third parties.
We believe our technology base, in combination with our know-how, and collaborative projects with major research institutions, will facilitate the development and commercialization of products for use in the treatment of a wide array of neurodegenerative conditions and in regenerative repair of acute disease.
Regenerative medicine is a young and emerging field. Regenerative medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. There can be no assurances that our intellectual property portfolio will ultimately produce viable commercialized products and processes. Even if we are able to produce a commercially viable product, there are strong competitors in this field and our products may not be able to successfully compete against them.
All of our research efforts to date are at the pre-clinical or clinical stage of development. We are focused on leveraging our key assets, including our intellectual property, our scientific team and our facilities, to advance our technologies. In addition, we are pursuing strategic collaborations with members of academia and industry.
Clinical Programs
Below is a description of our four most advanced clinical programs, their
intended indication, current stage of development and our expected future
development plans.
Future
Development
Program Indication Status Development Plan
NSI - 566 Amyotrophic Lateral Commenced Phase Anticipated to
Sclerosis (ALS) II clinical complete dosing of
trials. the Phase II
clinical trials
during the second
quarter of 2014
NSI - 566 Chronic Spinal Cord Approved to Phase I Trial
Injury commence Phase I expected to
clinical trials. commence during the
fourth quarter of
2013.
NSI - 566 Motor deficits due to Approved to Anticipated to
ischemic stroke commence commence trials
combined Phase during the fourth
I/II clinical quarter of 2013.
trials in China.
NSI - 189 Major Depressive Completed Phase Actively looking to
Disorder Ia, Phase Ib partner development
dosing complete. after Phase Ib
trial. Final data
expected during the
fourth quarter of
2013.
Thank you
T2M
Market Data 
Markets 
AI
